Kyu-pyo Kim

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

Yong Sang Hong, Byung‐Ho Nam, Kyu-pyo Kim et al. · The Lancet Oncology · 2014 · 383 citations

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +9

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Yong Sang Hong, Sun Young Kim, Ji Sung Lee et al. · Journal of Clinical Oncology · 2019 · 162 citations

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Ivana Yen, Jeeyun Lee, Yong Sang Hong et al. · Nature · 2021 · 133 citations · Full text

Raf Inhibitor Belvarafenib, Melanoma, Pathology +6

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

Yong Sang Hong, Young Suk Park, Ho Yeong Lim et al. · The Lancet Oncology · 2012 · 132 citations

Gastrointestinal Oncology, Medicine, Colorectal Cancer +7

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group

Changhoon Yoo, Hyeon-Su Im, Kyu-pyo Kim et al. · Therapeutic Advances in Medical Oncology · 2019 · 47 citations · Full text